Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Stock Rated “Moderate Buy” by Sell-Side Analysts

Posted by Geri Gentry on Oct 25th, 2026

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL – Get Free Report) has been given an average recommendation of “Moderate Buy” by the seven brokerages that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $29.50.

Several research analysts have recently issued reports on ANL shares. Loop Capital set a $49.00 target price on shares of Adlai Nortye in a report on Tuesday, September 8th. Wall Street Zen upgraded shares of Adlai Nortye from a “hold” rating to a “buy” rating in a research note on Saturday, October 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Adlai Nortye in a research note on Monday, October 12th. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Adlai Nortye in a research report on Tuesday, September 8th. Finally, Jefferies Financial Group raised shares of Adlai Nortye to a “strong-buy” rating in a research report on Monday, October 5th.

Check Out Our Latest Stock Analysis on ANL

Adlai Nortye Stock Performance

Shares of Adlai Nortye stock opened at $10.58 on Friday. Adlai Nortye has a 52 week low of $0.88 and a 52 week high of $17.25. The firm’s 50 day moving average is $14.20 and its two-hundred day moving average is $12.82.

Insider Activity

In other news, Director Ping Ji sold 10,000 shares of Adlai Nortye stock in a transaction dated Wednesday, September 30th. The stock was sold at an average price of $15.99, for a total transaction of $159,900.00. Following the sale, the director owned 121,453 shares in the company, valued at approximately $1,942,033.47. The trade was a 7.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Xiaofeng Ye sold 6,000 shares of Adlai Nortye stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $13.98, for a total value of $83,880.00. Following the sale, the chief financial officer owned 153,424 shares in the company, valued at $2,144,867.52. This trade represents a 3.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 26,881 shares of company stock worth $411,060.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Braidwell LP purchased a new stake in Adlai Nortye in the second quarter valued at approximately $9,145,000. Boone Capital Management LLC purchased a new position in shares of Adlai Nortye during the second quarter worth approximately $2,971,000. Seven Fleet Capital Management LP purchased a new position in shares of Adlai Nortye during the second quarter worth approximately $1,302,000. Affinity Asset Advisors LLC purchased a new position in shares of Adlai Nortye during the first quarter worth approximately $1,140,000. Finally, ADAR1 Capital Management LLC acquired a new position in shares of Adlai Nortye in the 1st quarter valued at $816,000. Hedge funds and other institutional investors own 35.21% of the company’s stock.

Adlai Nortye Company Profile

(Get Free Report)

Adlai Nortye (NASDAQ: ANL) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cancer and other serious diseases. The company’s research is centered on treatments designed to stimulate or enhance the immune system’s ability to identify and attack cancer cells.

Adlai Nortye’s pipeline includes buparlisib, an oral pan-class I phosphoinositide 3-kinase inhibitor being investigated in oncology. The company has evaluated buparlisib in combination with immunotherapy for patients with recurrent or metastatic head and neck squamous cell carcinoma.